ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1196

Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study

Chanakya Kodishala1, Stephanie Duong2, Cassondra Hulshizer2, Ryan Lennon2, Rabia Javed2, Maria Vassilaki2, Michelle Mielke3, John Davis2, Cynthia Crowson4 and Elena Myasoedova2, 1Mayo Clinic Rochester Minnesota, Rochester, MN, 2Mayo Clinic, Rochester, MN, 3Wake Forest University School of Medicine, Winston-Salem, NC, 4Mayo Clinic, Eyota, MN

Meeting: ACR Convergence 2022

Keywords: Aging, Cognitive dysfunction, Inflammation, rheumatoid arthritis, Smoking

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: Epidemiology and Public Health Poster II

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk of developing dementia. Systemic inflammation is implicated in the pathogenesis of cognitive decline. However, the association between inflammatory markers and dementia is inconsistent. Also, it is unclear whether inflammation directly contributes to dementia pathology or exerts its effects through other modifiable risk factors. We aimed to study the interaction of inflammatory burden with smoking and lipids as risk modifiers for dementia in an inception cohort of RA.

Methods: This retrospective population-based cohort study included residents of a geographical area who were ≥50 years when they met 1987 ACR criteria for incident RA in 1980-2014. All patients were followed until death/migration or 12/31/2019. Those with dementia before RA incidence were excluded (n=12). Incident dementia was defined as two relevant ICD-9/10 codes at least 30 days apart. Data on socio-demographics, rheumatoid factor (RF)/anti-cyclic citrullinated peptide (anti-CCP) positivity, smoking (current and former), cardio/cerebrovascular disease (CVD), erythrocyte sedimentation rate (ESR), and lipid measures were abstracted from medical records. Cumulative inflammatory burden was estimated by applying the most recent ESR value to each day of follow-up and summing these values. CVD was defined as coronary heart disease/ischemic stroke/CVD death/intermittent claudication/heart failure. Cox models with time-dependent covariates were used to examine association between cumulative ESR and dementia, adjusting for age, sex, and year of RA incidence. Interactions between cumulative ESR or highest ESR in the first year of RA and smoking or lipid measures, i.e., total cholesterol, low and high-density lipoprotein cholesterol (LDL, HDL), triglycerides were also assessed.

Results: The study included 886 patients with RA (mean age 65 years, 65% females, 95% Whites); 63% were RF/anti-CCP positive. While cumulative ESR was not associated with development of dementia (HR 1.03, 95% CI 0.97-1.09) in the total sample, it was significantly associated with increased risk of dementia among smokers (interaction p=0.03; Figure). Adjusting for CVD, the interaction effect persisted but was no longer statistically significant. In patients with seropositive RA, cumulative ESR and ever smoking interacted to increase the risk of dementia (p=0.04). There was a statistically significant interaction between the highest ESR in the first year of RA and baseline LDL (p=0.02), wherein high LDL was associated with increased risk of dementia among patients with normal ESR but with decreased risk of dementia among those with high ESR. No such interactions were found for other lipid measures.

Conclusion: Cumulative inflammation interacts with smoking, resulting in increased risk of dementia. Similarly, there is an interaction between highest ESR and LDL on the risk of dementia. Lipids may have paradoxical association with risk of dementia in RA with potential implications for dementia risk estimation in patients with elevated ESR. Our findings highlight the important role of modifiable risk factors and systemic inflammation in the pathogenesis of dementia in patients with RA.

Supporting image 1

Figure: Interaction of cumulative ESR and smoking


Disclosures: C. Kodishala, None; S. Duong, None; C. Hulshizer, None; R. Lennon, None; R. Javed, None; M. Vassilaki, F. Hoffmann-La Roche, Biogen, F. Hoffmann-La Roche, Avobis Bio, LLC., Amgen, Abbott Laboratories, Johnson and Johnson, Medtronic, AbbVie; M. Mielke, LabCorp, Biogen; J. Davis, Pfizer; C. Crowson, None; E. Myasoedova, None.

To cite this abstract in AMA style:

Kodishala C, Duong S, Hulshizer C, Lennon R, Javed R, Vassilaki M, Mielke M, Davis J, Crowson C, Myasoedova E. Interaction of Cumulative Inflammation with Smoking and Lipids in Risk Modification of Dementia Among Patients with Rheumatoid Arthritis: A Population-based Cohort Study [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/interaction-of-cumulative-inflammation-with-smoking-and-lipids-in-risk-modification-of-dementia-among-patients-with-rheumatoid-arthritis-a-population-based-cohort-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/interaction-of-cumulative-inflammation-with-smoking-and-lipids-in-risk-modification-of-dementia-among-patients-with-rheumatoid-arthritis-a-population-based-cohort-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology